Zymeworks Inc. Common Stock (ZYME)
Stock · NASDAQ · Health Care
$25.03as of 10/16/2026
Price chart
Active signals
ZYME Signal Track Record
How signals performed across all stocks →What ZYME's price did in the 20 trading sessions after each past signal, compared with any 20-session window over the same period.
| Signal | Times | Median 20-session return | Higher after 20 sessions | Last signal |
|---|---|---|---|---|
| Volume Spike | 34 | +4.3% | 68% | September 17, 2026 |
| Bollinger Band Breakout | 26 | +2.9% | 65% | August 13, 2026 |
| Bollinger Band Breakdown | 15 | +0.2% | 53% | June 9, 2026 |
| 200-Day Moving Average TouchActive now | 14 | -0.6% | 50% | October 2, 2026 |
| Any 20-session window (baseline) | +3.1% | 59% |
Computed by MarketWall from daily closing prices since May 18, 2022. Returns are close-to-close and don't include dividends. Past results describe what happened before; they are not a forecast and not investment advice.
About ZYME
Zymeworks Inc., a biotechnology company, develops biotherapeutics for the treatment of cancer, inflammation, and autoimmune diseases. The company's platforms include Azymetric multispecific antibody platform; Drug Conjugate platform that includes a suite of proprietary cytotoxins comprising topoisomerase and microtubulin inhibiting toxins, stable linkers, and conjugation technologies; EFECT platform, which consists o…
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- Employees
- 231
- Website
- www.zymeworks.com/
Fundamentals
- 1-day range
- $24.94$25.85
- Market cap
- $1.69B
- P/E (trailing)
- —
- P/E (forward)
- 23.69
- EPS (trailing)
- $-2.01
- Dividend yield
- —
- Beta
- 1.32
- Avg. volume
- 784.5K
How Zymeworks Inc. Common Stock Makes Money
Where the revenue actually goes — FY2025 annual results
Source: 10-K filed Mar 2, 2026 · via SEC EDGAR / Finnhub
Forecasts
14 analyst ratings
Zymeworks Inc. Common Stock Competitors
Chosen by industry and closest market cap.
- ZYMEZymeworks Inc. Common Stock$25.03▼ 2.80%Market cap $1.69BP/E —$16$31.34
- PRGOPerrigo Company plc Ordinary Shares$16.63▲ 0.91%Market cap $1.74BP/E —$9.23$22.02
- ANABAnaptysBio Inc. Common Stock$46.61▼ 4.31%Market cap $1.62BP/E 7.14$20.18$72.36
- MRVIMaravai LifeSciences Holdings Inc. Class A Common Stock$6.79▼ 3.96%Market cap $1.61BP/E —$2.55$9.42
- SNDXSyndax Pharmaceuticals Inc. Common Stock$12.9▼ 5.49%Market cap $1.76BP/E —$12.99$25.59
- TYRATyra Biosciences Inc. Common Stock$18.52▼ 2.73%Market cap $1.61BP/E —$12.96$40.65
- SRPTSarepta Therapeutics Inc. Common Stock (DE)$17.1▼ 3.88%Market cap $1.77BP/E —$14.68$24.68
| Symbol | Market cap | P/E ratio | Price | 1D | 52-week range |
|---|---|---|---|---|---|
| ZYME Zymeworks Inc. Common Stock | $1.69B | — | $25.03 | ▼ 2.80% | $16$31.34 |
| PRGO Perrigo Company plc Ordinary Shares | $1.74B | — | $16.63 | ▲ 0.91% | $9.23$22.02 |
| ANAB AnaptysBio Inc. Common Stock | $1.62B | 7.14 | $46.61 | ▼ 4.31% | $20.18$72.36 |
| MRVI Maravai LifeSciences Holdings Inc. Class A Common Stock | $1.61B | — | $6.79 | ▼ 3.96% | $2.55$9.42 |
| SNDX Syndax Pharmaceuticals Inc. Common Stock | $1.76B | — | $12.9 | ▼ 5.49% | $12.99$25.59 |
| TYRA Tyra Biosciences Inc. Common Stock | $1.61B | — | $18.52 | ▼ 2.73% | $12.96$40.65 |
| SRPT Sarepta Therapeutics Inc. Common Stock (DE) | $1.77B | — | $17.1 | ▼ 3.88% | $14.68$24.68 |
P/E shows — for peers not currently carrying a live signal of their own.
Latest news
- Zymeworks (ZYME) Could Be 39% Undervalued On 2026 Revenue Guidance And CIO HireYahoo · 10/9/2026
- Truist Securities Maintains Buy on Zymeworks, Raises Price Target to $34benzinga · 10/7/2026
- Truist Securities Maintains Buy on Zymeworks, Raises Price Target to $34Benzinga · 10/7/2026
- Zymeworks Completes Theravance Deal, Adds YUPELRI Cash Flow and Raises 2026 OutlookYahoo · 10/2/2026
- Citigroup Maintains Buy on Zymeworks, Raises Price Target to $39Benzinga · 9/29/2026
- Zymeworks Inc. (ZYME) M&A Call TranscriptSeekingAlpha · 9/28/2026
- Zymeworks Updates Annual Financial Targets After Finalizing Theravance Biopharma DealBenzinga · 9/28/2026
- Zymeworks Announces Updated 2026 Financial Guidance and Final Transaction Details Following Theravance Biopharma AcquisitionYahoo · 9/28/2026
- Zymeworks Inc. (ZYME) Theravance Biopharma, Inc. - M&A Call - SlideshowSeekingAlpha · 9/28/2026
Insider Activity
Insider Actions →- Schayowitz Adam · October 9, 2026 · Option Exercise37.0K
- Schayowitz Adam · October 9, 2026 · Sale13.8K @ $25.85
- Mark Hollywood · July 6, 2026 · Grant939 @ $22.22
- Schneider Paul R · May 13, 2026 · Grant119.0K
- Schneider Paul R · May 13, 2026 · Grant178.0K
Institutional Ownership
March 31, 2026
- Total shares held
- 70.02M
- Total value held
- $1.74B
- Institutional holders
- 207
- Unknown22.97M
- Unknown7.00M
- Unknown4.55M
- Unknown3.73M
- Unknown3.51M
- Unknown2.48M
- Unknown1.91M
- Unknown1.71M
- Unknown1.25M
- Unknown1.14M
See the full, filterable feed with live charts on the MarketWall dashboard.
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 13, 2026
ZYME News Highlights Potential Undervaluation and Raised Price Target
Recent coverage notes that Zymeworks may be about 39% undervalued based on its 2026 revenue guidance and the recent appointment of a chief investment officer. Truist Securities also kept its rating and lifted its price target to $34, reflecting continued confidence in the company's outlook.
ZYME News Highlights Potential Undervaluation and Raised Price Target. Recent coverage notes that Zymeworks may be about 39% undervalued based on its 2026 revenue guidance and the recent appointment of a chief investment officer. Truist Securities also kept its rating and lifted its price target to $34, reflecting continued confidence in the company's outlook.